These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1135 related items for PubMed ID: 19227433

  • 1. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
    Alberú J, Morales-Buenrostro LE, Correa-Rotter R, Muñoz-Trejo T, Zúñiga-Varga J, Cuéllar-González JV, Mayorga-Madrigal H, Vanegas-Carrero R, Aranda F, Rodríguez-Romo R, Herrera-Garcia C, González-Michaca L, Sierra-Madero JG.
    Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
    [Abstract] [Full Text] [Related]

  • 2. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [Abstract] [Full Text] [Related]

  • 3. Sequential cytomegalovirus antigenemia monitoring in kidney transplant patients treated with antilymphocyte antibodies.
    Ozaki KS, Pestana JO, Granato CF, Pacheco-Silva A, Camargo LF.
    Transpl Infect Dis; 2004 Jun; 6(2):63-8. PubMed ID: 15522106
    [Abstract] [Full Text] [Related]

  • 4. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E, Suter F, Baruzzo S, Perani V, Moioli F, Remuzzi G.
    Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [Abstract] [Full Text] [Related]

  • 5. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
    Reischig T, Jindra P, Hes O, Bouda M, Kormunda S, Treska V.
    Transplantation; 2009 Feb 15; 87(3):436-44. PubMed ID: 19202451
    [Abstract] [Full Text] [Related]

  • 6. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
    Fricke L, Steinhoff J, Hartwig-Weber I, Bein G.
    Dtsch Med Wochenschr; 1997 May 02; 122(18):565-71. PubMed ID: 9190308
    [Abstract] [Full Text] [Related]

  • 7. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
    Torre-Cisneros J, Caston-Osorio JJ, Martín C, Rivero A, Doblas A, Rojas R, Gómez P, Martínez F, Torres A.
    Enferm Infecc Microbiol Clin; 2010 Jan 02; 28(1):6-12. PubMed ID: 19409666
    [Abstract] [Full Text] [Related]

  • 8. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.
    Transpl Infect Dis; 2010 Aug 01; 12(4):322-9. PubMed ID: 20487414
    [Abstract] [Full Text] [Related]

  • 9. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
    Tan BH, Chlebicka NL, Low JG, Chong TY, Chan KP, Goh YT.
    Transpl Infect Dis; 2008 Oct 01; 10(5):325-32. PubMed ID: 18627578
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients.
    Casillo R, Grimaldi M, Ragone E, Maiello C, Marra C, De Santo L, Amarelli C, Romano G, Della Corte A, Portella G, Tripodi MF, Fortunato R, Cotrufo M, Utili R.
    Transplant Proc; 2004 Apr 01; 36(3):651-3. PubMed ID: 15110622
    [Abstract] [Full Text] [Related]

  • 11. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ, Malaise J, Moreno A, Crespo M, Fernández-Cruz L, Euro-SPK Study Group.
    Nephrol Dial Transplant; 2005 May 01; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [Abstract] [Full Text] [Related]

  • 12. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
    Iberer F, Tscheliessnigg KH, Halwachs G, Auer T, Wasler A, Petutschnigg B, Müller H, Freigassner M, Allmayr T, Hipmair G.
    Wien Klin Wochenschr; 1995 May 01; 107(23):718-22. PubMed ID: 8560893
    [Abstract] [Full Text] [Related]

  • 13. Monitoring of human Cytomegalovirus infection by antigenemia and viremia in the first 100 days following renal transplantation and relation to antiviral strategies.
    Terlizzi ME, Costa C, Astegiano S, Sidoti F, Vendrame R, Segoloni GP, Bergallo M, Cavallo R.
    Minerva Med; 2008 Jun 01; 99(3):231-9. PubMed ID: 18497721
    [Abstract] [Full Text] [Related]

  • 14. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up.
    Zaia JA, Schmidt GM, Chao NJ, Rizk NW, Nademanee AP, Niland JC, Horak DA, Lee J, Gallez-Hawkins G, Kusnierz-Glaz CR.
    Biol Blood Marrow Transplant; 1995 Dec 01; 1(2):88-93. PubMed ID: 9118297
    [Abstract] [Full Text] [Related]

  • 15. Cytomegalovirus infection in kidney transplant recipients: Evolution of approach through three eras.
    Boucher A, Lord H, Collette S, Morin M, Dandavino R.
    Transplant Proc; 2006 Dec 01; 38(10):3506-8. PubMed ID: 17175316
    [Abstract] [Full Text] [Related]

  • 16. [pp65 antigenemia in evaluation of cytomegalovirus infection after kidney transplantation].
    Orlić P, Dvornik S, Husnjak SC, Aralica M, Orlić L, Zivcić-Cosić S, Sladoje-Martinović B, Fućak M.
    Acta Med Croatica; 2003 Dec 01; 57(1):49-52. PubMed ID: 12876863
    [Abstract] [Full Text] [Related]

  • 17. [The prognostic value of cytomegalovirus antigenemia and viremia for the development of cytomegalovirus disease and the survival of AIDS patients].
    Cartón JA, Maradona JA, de Oña M, Asensi V, Melón S, García-Alcalde ML, Rodríguez-Junquera M, Moreno-Torrico A, de Zárraga M.
    Med Clin (Barc); 1999 Sep 04; 113(6):205-9. PubMed ID: 10472608
    [Abstract] [Full Text] [Related]

  • 18. Cytomegalovirus-specific CD8+ T cells do not develop in all renal transplant patients at risk of virus infection.
    Christmas SE, Halliday D, Lawton N, Wang H, Abdalla I, Masters J, Hassan RL, Hart IJ, Khan N, Smith J, Hammad A, Bakran A.
    Transpl Immunol; 2009 Dec 04; 22(1-2):99-104. PubMed ID: 19635559
    [Abstract] [Full Text] [Related]

  • 19. Role of antigenemia assay in the early diagnosis and treatment of CMV infection in renal transplant patients.
    Chiaramonte S, Pellizzer G, Rassu M, Dissegna D, Bragantiini L, Zuccarotto D, La Greca G.
    Clin Nephrol; 2000 Apr 04; 53(4):suppl 10-2. PubMed ID: 10809428
    [Abstract] [Full Text] [Related]

  • 20. The effect of cytomegalovirus antigenemia titer on the efficacy of preemptive therapy for the prevention of cytomegalovirus disease after kidney transplantation.
    Jung GO, Kim SJ, Choi GS, Moon JI, Kim JM, Sin MJ, Kim EY, Kwon CH, Joh JW, Lee SK.
    Transplant Proc; 2010 Apr 04; 42(3):804-10. PubMed ID: 20430177
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.